PMID: 8587293Dec 1, 1995Paper

Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials

Kidney International. Supplement
G M Danovitch

Abstract

Following promising preclinical and Phase I clinical trials of mycophenolate mofetil (MMF) in solid organ transplantation a series of pivotal randomized trials were commenced to determine the place of this new immunosuppressant in clinical kidney transplantation. The trials in the USA used MMF in combination with prednisone and cyclosporine for rejection prevention, for the treatment of a first acute rejection, and for the treatment of refractory rejection. Results of the primary end-point of the rejection prevention study and from the 12 months follow-up of the refractory rejection study are now available for analysis. In the rejection prevention study, which was double-blinded and placebo-controlled, the addition of either 2 g or 3 g of MMF daily to a standard regimen of cyclosporine and prednisone reduced the incidence of a first acute rejection by approximately 50% during the first six months post-transplant. There were also impressive reductions in the use of steroids and anti-lymphocytic agents. The 2 g daily dose was best tolerated and demonstrated a safety profile similar to that of azathioprine. The addition of 3 g MMF daily was effective treatment for refractory acute rejection and, compared to treatment with intraven...Continue Reading

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.